TNFR2 associates with FoxP3 stability and identifies asubset of regulatory T cells that are specifically expanded by anti-TNF treatments in rheumatoid arthritis.
To study the involvement of regulatory T cells (Tregs) expressing tumor necrosis factor-αreceptor 2 (TNFR2) incontrol of experimental inflammation and response to treatment in rheumatoid arthritis (RA) and spondyloarthritis (SpA). The role of TNFR2 inTregswas exploredusing amultilevel translational approach.Tregstability was evaluatedby analyzing methylation status of the foxp3locus by bisulfite sequencing. Two models of inflammation (imiquimod-induced skin inflammationand delayed type hypersensitivity arthritis, DTHA) were induced inTNFR2-deficient (TNFR2-/- ) micewith or without transfer of purified CD4+ CD25+ cellsfrom wild-type (wt) mice.The evolution of the TNFR2+ Tregpopulation before and after targetedtreatment was monitored in individuals with RA andSpA. Foxp3gene methylation was greaterin Tregs from TNFR2-/- (50%) thanwt(36,7%)mice. In cultured Tregs, TNF-α enhanced Foxp3 expression maintenance and proliferation through TNFR2 signaling. Imiquimod-induced skin inflammation and DTHA were aggravated in TNFR2-/- mice as compared to wt mice (p<0.05 for skin inflammation and p<0.0001 for ankle swelling during DTHA).Adoptive transfer of wtTregs into TNFR2-/- mice prevented from arthritis aggravation. TNFR2+ Tregfrequency was increased (p<0.01)at 3 months (65.2 ± 3.1) of anti-TNF-α treatments vs. the baseline(49.1 ± 5.5) in RA individuals, but not in those receiving tocilizumab. In contrast, in anti-TNF-αtreated SpAindividuals, TNFR2+ Tregfrequency was not modified. TNFR2 expression identifies a subset of Tregscharacterized by stable expression of Foxp3 via genehypomethylation, whose adoptive transfer ameliorates experimental inflammation. Expansion and activation of these TNFR2+ Tregs may be one of the mechanisms by which anti-TNF-α agents control inflammation in RA but not SpA.